Experience in vaccination against COVID-19 in people with a history of allergy
e202310081
Keywords:
Vaccine against COVID-19, Adverse events, Allergic reactions, Allergy history, Anaphylaxis, Hypersensitivity reactions, Telephone surveyAbstract
BACKGROUND // A common consultation since the beginning of the vaccination campaign against COVID-19 was related to people with a history of allergy to drugs or other vaccines. The objective of the study was to describe what happened after the administration of the vaccine against COVID-19 in people with a history of moderate and severe allergy, vaccinated against COVID-19 in a Primary Care Emergency Center (PCEC).
METHODS // Observational descriptive study with sixty-four people with a history of moderate and severe allergy was carried out, vaccinated in PCEP, between May and October 2021, in the Barcelonés Nord and Maresme (Barcelona province), after assessment by primary care pharmacologists and pharmacists. The percentage of people with adverse events that occurred after vaccination during their stay in the PCEP, the types detected and severity were calculated. Subsequently, a telephone survey was conducted to determine patient satisfaction. A descriptive analysis (calculation of proportions) was performed.
RESULTS // The mean age of 49.7 years (from twelve to ninety-four years) and 90.6% were women. 87.5% of the administered vaccines were Comirnaty®. Adverse events occurring after vaccination were detected in fifteen patients (23.4%), of whom four (6.25%) were manifestations of hypersensitivity, all classified as mild. The reasons for vaccination were a history of allergy to NSAIDs (45.3%), antibiotics (32.8%), analgesics (17.2%), vaccines (28.1%), other substances (40.6%) and anaphylaxis (26.6%). The degree of general satisfaction was 9.11 (out of 10).
CONCLUSIONS // The percentage of patients with a history of anaphylaxis and allergic drug reactions who present hypersensitivity reactions to COVID-19 vaccines is 6.25% and all are mild.
Downloads
References
Estrategia de vacunación frente a COVID-19 en España. Actualización 7. https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/covid19/Actualizaciones_Estrategia_Vacunacion/docs/COVID-19_Actualizacion7_EstrategiaVacunacion.pdf
Ficha técnica Comirnaty®. https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_es.pdf
Cabanillas B, Akdis CA, Novak N. Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol? Allergy 2021 Jun;76(6):1617-1618. doi: https://dx.doi.org/10.1111/all.14711. PMID: 33320974.
Ficha técnica COVID-19 Vaccine Janssen®. https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-janssen-epar-product-information_es.pdf
Ficha técnica Vaxzevria®. https://cima.aemps.es/cima/pdfs/es/ft/1211529001/FT_1211529001.pdf
Greenhawt M, Abrams EM, Shaker M, Chu DK, Khan D, Akin C et al. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract 2021 Oct;9(10):3546-3567. doi: https://dx.doi.org/10.1016/j.jaip.2021.06.006. Epub 2021 Jun 18. PMID: 34153517; PMCID: PMC8248554.
Ficha técnica COVID-19 Vaccine Moderna®. https://ec.europa.eu/health/documents/community-register/2021/20210106150575/anx_150575_es.pdf
Cabanillas B, Novak N. Allergy to COVID-19 vaccines: A current update. Allergol Int. 2021 Jul; 70(3):313-318. doi: https://dx.doi.org/10.1016/j.alit.2021.04.003. Epub 2021 Apr 23. PMID: 33962863; PMCID: PMC8062405.
Sokolowska M, Eiwegger T, Ollert M, Torres MJ, Barber D, Del Giacco S et al. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. Allergy. 2021 Jun; 76(6):1629-1639. doi: https://dx.doi.org/10.1111/all.14739. PMID: 33452689; PMCID: PMC8013422.
Worm M, Bauer A, Wedi B, Treudler R, Pfuetzner W, Brockow K et al. Practical recommendations for the allergological risk assessment of the COVID-19 vaccination-a harmonized statement of allergy centers in Germany. Allergol Select. 2021 Jan 26; 5:72-76. doi: https://dx.doi.org/10.5414/ALX02225E. PMID: 33521511; PMCID: PMC7841415.
Bonadonna P, Brockow K, Niedoszytko M, Elberink HO, Akin C, Nedoszytko B et al. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). J Allergy Clin Immunol Pract. 2021 Jun; 9(6):2139-2144. doi: https://dx.doi.org/10.1016/j.jaip.2021.03.041. Epub 2021 Apr 5. PMID: 33831618; PMCID: PMC8019658.
CDC. U.S. COVID-19 Vaccine Product Information. https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html
Sociedad Española de Alergología e Inmunología Clínica (SEAIC). Comunicado en relación con las vacunas de Pfizer-BioNTech, Moderna y AstraZeneca, en pacientes con historial alérgico. https://www.seaic.org/inicio/sala-de-prensa/vacuna-covid-19-y-pacientes-con-historial-de-alergia-grave.html
Pawankar R, Canonica GW, Holgate ST, Lockey RF, Blaiss MS. White Book on Allergy. World Allergy Organ 2013. https://www.worldallergy.org/UserFiles/file/ExecSummary-2013-v6-hires.pdf. Consultado 10 May 2022.
Luxi N, Giovanazzi A, Capuano A, Crisafulli S, Cutroneo PM, Fantini MP et al. COVID19 collaborating group. COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety. Drug Saf 2021 Dec; 44 (12):1247-1269. doi: https://dx.doi.org/10.1007/s40264-021-01131-6. Epub 2021 Nov 5. PMID: 34739716; PMCID: PMC8569292.
Sampath V, Rabinowitz G, Shah M, Jain S, Diamant Z, Jesenak M et al. Vaccines and allergic reactions: the past, the current COVID-19 pandemic, and future perspectives. Allergy 2021 Jun;76(6):1640-1660. doi: https://dx.doi.org/10.1111/all.14840. Epub 2021 Jun 4. PMID: 33811364; PMCID: PMC8251022.
CDC. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine-United States, December 14-23, 2020. Weekly/January 15, 2021/70(2);46-51. https://www.cdc.gov/mmwr/volumes/70/wr/mm7002e1.htm
CDC. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine-United States, December 21, 2020-January 10, 2021. Weekly / January 29, 2021 / 70(4); 125-129. https://www.cdc.gov/mmwr/volumes/70/wr/mm7004e1.htm
Risma KA. COVID-19 mRNA vaccine allergy. Curr Opin Pediatr. 2021 Dec 1;33(6):610-617. doi: https://dx.doi.org/10.1097/MOP.0000000000001077. PMID: 34670264; PMCID: PMC8577302.
Rojas-Pérez-Ezquerra P, Crespo Quirós J, Tornero Molina P, Baeza Ochoa de Ocáriz ML, Zubeldia Ortuño JM. Safety of New mRNA Vaccines Against COVID-19 in Severely Allergic Patients. J Investig Allergol Clin Immunol 2021 Apr 20; 31 (2):180-181. doi: https://dx.doi.org/10.18176/jiaci.0683. Epub 2021 Mar 2. PMID: 33648905.
Wentrys Ł, Stopyra L. COVID-19 vaccination including 198 patients with history of severe anaphylactic reaction-own observations. Przegl Epidemiol 2021; 75 (3):315-325. doi: https://dx.doi.org/10.32394/pe.75.28. PMID: 35170287.
Li L, Robinson LB, Patel R, Landman AB, Fu X, Shenoy ES et al. Association of Self-reported High-Risk Allergy History With Allergy Symptoms After COVID-19 Vaccination. JAMA Network Open 2021 Oct 1; 4 (10):e2131034. doi: https://dx.doi.org/10.1001/jamanetworkopen.2021.31034. PMID: 34698847; PMCID: PMC8548941.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Juan Antonio García Vicente, Cristina Vedia Urgell, Roser Vallès Fernández, Cristina Morgado Ramos, Esther Moral Roldán, Soraya Marchal Torralbo, Magda Lladó Blanch, Anna Marchal Torralbo, Thatiana Vértiz Guidotti, Josep Sorribes López
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.